Pharming Group

Pharming Group Enterprise Value

The Enterprise Value (EV) of Pharming Group (PHAR) as of Nov 20, 2026 is 840.32 M USD. In the previous year, Enterprise Value (EV) was 846.80 M USD — a change of -0.77% (lower).

Enterprise Value

840.32 MUSD

YoY

-0.77%

Last updated:

Enterprise Value (EV) of Pharming Group is 2025 840.32 M USD. Enterprise Value (EV) of Pharming Group was 2024 846.80 M USD. It decreases by -0.77% lower compared to the previous year.

The Pharming Group Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
907.47 M USD
Jan 1, 2019
888.21 M USD
Jan 1, 2020
868.99 M USD
Jan 1, 2021
870.16 M USD
Jan 1, 2022
863.71 M USD
Jan 1, 2023
862.48 M USD
Jan 1, 2024
846.80 M USD
Jan 1, 2025
840.32 M USD
The Pharming Group Enterprise Value history
YEAREnterprise ValueYoY
840.32 MUSD-0.77%
846.80 MUSD-1.82%
862.48 MUSD-0.14%
863.71 MUSD-0.74%
870.16 MUSD+0.13%
868.99 MUSD-2.16%
888.21 MUSD-2.12%
907.47 MUSD-0.95%
916.20 MUSD-2.35%
938.21 MUSD+5.94%
885.63 MUSD+2.42%
864.72 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharming Group Stock analysis

What does Pharming Group do? Pharming Group N.V. generates revenue through the development and commercialization of protein replacement therapies and precision medicines for rare diseases. Its lead product, RUCONEST, is a recombinant C1 esterase inhibitor used to treat acute hereditary angioedema (HAE) attacks in adult and adolescent patients. The company also markets Joenja (leniolisib), an oral small molecule PI3K inhibitor for activated phosphoinositide 3-kinase delta syndrome. Pharming collaborates with Novartis under a development collaboration and license agreement, which likely contributes to its revenue streams. The company serves patients with rare diseases across the United States, Europe, and internationally through its therapeutic offerings. RUCONEST targets acute HAE attacks in adult and adolescent patients, while Joenja addresses activated phosphoinositide 3-kinase delta syndrome. Both products are commercialized by Pharming Group N.V. in the United States, Europe, and internationally. The development collaboration and license agreement with Novartis supports the company's product pipeline and revenue generation. Pharming focuses on rare disease treatments, leveraging its expertise in protein replacement therapies and precision medicines to address unmet medical needs. Pharming Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharming Group stock

Enterprise Value (EV) of Pharming Group is 840.32 M USD in 2025.

Enterprise Value (EV) of Pharming Group changed from 846.80 M USD to 840.32 M USD, representing a -0.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Pharming Group since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Pharming Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Pharming Group

All Key Metrics — Pharming Group